Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.05
TECH's Cash to Debt is ranked higher than
57% of the 1275 Companies
in the Global Biotechnology industry.

( Industry Median: 69.96 vs. TECH: 1.05 )
TECH' s 10-Year Cash to Debt Range
Min: 1.05   Max: No Debt
Current: 1.05

Equity to Asset 0.78
TECH's Equity to Asset is ranked higher than
77% of the 970 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. TECH: 0.78 )
TECH' s 10-Year Equity to Asset Range
Min: 0.69   Max: 0.98
Current: 0.78

0.69
0.98
F-Score: 4
Z-Score: 11.72
M-Score: -3.87
WACC vs ROIC
5.81%
18.48%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 40.88
TECH's Operating margin (%) is ranked higher than
96% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -71.67 vs. TECH: 40.88 )
TECH' s 10-Year Operating margin (%) Range
Min: 19.71   Max: 58.1
Current: 40.88

19.71
58.1
Net-margin (%) 28.23
TECH's Net-margin (%) is ranked higher than
95% of the 1050 Companies
in the Global Biotechnology industry.

( Industry Median: -75.86 vs. TECH: 28.23 )
TECH' s 10-Year Net-margin (%) Range
Min: 14.05   Max: 40.8
Current: 28.23

14.05
40.8
ROE (%) 13.98
TECH's ROE (%) is ranked higher than
93% of the 1159 Companies
in the Global Biotechnology industry.

( Industry Median: -33.71 vs. TECH: 13.98 )
TECH' s 10-Year ROE (%) Range
Min: 14.12   Max: 27.17
Current: 13.98

14.12
27.17
ROA (%) 12.51
TECH's ROA (%) is ranked higher than
95% of the 1279 Companies
in the Global Biotechnology industry.

( Industry Median: -27.24 vs. TECH: 12.51 )
TECH' s 10-Year ROA (%) Range
Min: 11.96   Max: 23.99
Current: 12.51

11.96
23.99
ROC (Joel Greenblatt) (%) 78.30
TECH's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1249 Companies
in the Global Biotechnology industry.

( Industry Median: -347.70 vs. TECH: 78.30 )
TECH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 45.33   Max: 112.73
Current: 78.3

45.33
112.73
Revenue Growth (3Y)(%) 7.40
TECH's Revenue Growth (3Y)(%) is ranked higher than
82% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: -0.50 vs. TECH: 7.40 )
TECH' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.4   Max: 16.4
Current: 7.4

5.4
16.4
EBITDA Growth (3Y)(%) 1.60
TECH's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. TECH: 1.60 )
TECH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 1.6   Max: 41.3
Current: 1.6

1.6
41.3
EPS Growth (3Y)(%) -0.20
TECH's EPS Growth (3Y)(%) is ranked higher than
80% of the 708 Companies
in the Global Biotechnology industry.

( Industry Median: -8.20 vs. TECH: -0.20 )
TECH' s 10-Year EPS Growth (3Y)(%) Range
Min: -0.2   Max: 36.3
Current: -0.2

-0.2
36.3
» TECH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

TECH Guru Trades in Q1 2014

Jeremy Grantham 46,243 sh (+371.87%)
Bill Frels 995,851 sh (+7.13%)
Columbia Wanger 763,700 sh (unchged)
Ron Baron 1,053,380 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Paul Tudor Jones 3,400 sh (unchged)
RS Investment Management Sold Out
Chuck Royce 652,000 sh (-8.78%)
Jim Simons 577,700 sh (-24.19%)
» More
Q2 2014

TECH Guru Trades in Q2 2014

Paul Tudor Jones 5,500 sh (+61.76%)
Columbia Wanger 1,212,200 sh (+58.73%)
Bill Frels 1,095,391 sh (+10%)
Jeremy Grantham 48,243 sh (+4.32%)
Ron Baron 1,053,380 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Chuck Royce 641,750 sh (-1.57%)
Jim Simons 510,100 sh (-11.7%)
» More
Q3 2014

TECH Guru Trades in Q3 2014

Ray Dalio 2,300 sh (New)
Paul Tudor Jones 7,200 sh (+30.91%)
Columbia Wanger 1,332,700 sh (+9.94%)
Ron Baron 1,053,380 sh (unchged)
Ruane Cunniff 2,540 sh (unchged)
Bill Frels 1,090,022 sh (-0.49%)
Jim Simons 494,500 sh (-3.06%)
Chuck Royce 620,205 sh (-3.36%)
Jeremy Grantham 39,041 sh (-19.07%)
» More
Q4 2014

TECH Guru Trades in Q4 2014

Ray Dalio 3,982 sh (+73.13%)
Bill Frels 1,295,420 sh (+18.84%)
Columbia Wanger 1,483,300 sh (+11.3%)
Jim Simons 526,700 sh (+6.51%)
Ruane Cunniff 2,540 sh (unchged)
Ron Baron 1,053,220 sh (-0.02%)
Chuck Royce 611,825 sh (-1.35%)
Paul Tudor Jones 5,600 sh (-22.22%)
Jeremy Grantham 28,400 sh (-27.26%)
» More
» Details

Insider Trades

Latest Guru Trades with TECH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ray Dalio 2014-12-31 Add 73.13%$87.77 - $94.88 $ 97.547%3982
Ray Dalio 2014-09-30 New Buy$89.24 - $96.69 $ 97.544%2300
Joel Greenblatt 2013-12-31 Sold Out 0.02%$77.53 - $94.3 $ 97.5413%0
Joel Greenblatt 2013-09-30 Reduce -87.53%0.12%$69.64 - $81.28 $ 97.5428%5869
Jeff Ubben 2013-09-30 Sold Out 0.04%$69.64 - $81.28 $ 97.5428%0
Ruane Cunniff 2013-09-30 New Buy$69.64 - $81.28 $ 97.5428%2540
Jeff Ubben 2013-06-30 New Buy0.04%$63.42 - $69.44 $ 97.5447%62004
Chris Davis 2013-06-30 Sold Out 0.01%$63.42 - $69.44 $ 97.5447%0
Joel Greenblatt 2013-03-31 Add 134.75%0.09%$66.48 - $71.68 $ 97.5442%45922
Chris Davis 2013-03-31 Add 42.62%$66.48 - $71.68 $ 97.5442%33973
Joel Greenblatt 2012-09-30 New Buy0.12%$67 - $75.98 $ 97.5436%24249
Joel Greenblatt 2012-06-30 Sold Out 0.06%$64.98 - $74.23 $ 97.5443%0
Chuck Akre 2012-03-31 Sold Out 0.53%$66.13 - $71.99 $ 97.5450%0
John Hussman 2012-03-31 Sold Out 0.05%$66.13 - $71.99 $ 97.5450%0
Joel Greenblatt 2012-03-31 Add 47.81%0.02%$66.13 - $71.99 $ 97.5450%8941
John Hussman 2011-12-31 New Buy0.05%$62.37 - $73.55 $ 97.5444%44000
Joel Greenblatt 2011-12-31 New Buy0.05%$62.37 - $73.55 $ 97.5444%6049
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 33.50
TECH's P/E(ttm) is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 33.50 )
TECH' s 10-Year P/E(ttm) Range
Min: 16.76   Max: 34.05
Current: 33.5

16.76
34.05
Forward P/E 26.32
TECH's Forward P/E is ranked higher than
93% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 26.32 )
N/A
PE(NRI) 33.70
TECH's PE(NRI) is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 33.70 )
TECH' s 10-Year PE(NRI) Range
Min: 16.78   Max: 34.09
Current: 33.7

16.78
34.09
P/B 4.50
TECH's P/B is ranked higher than
79% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. TECH: 4.50 )
TECH' s 10-Year P/B Range
Min: 3.27   Max: 8.27
Current: 4.5

3.27
8.27
P/S 9.40
TECH's P/S is ranked higher than
84% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 29.06 vs. TECH: 9.40 )
TECH' s 10-Year P/S Range
Min: 6.73   Max: 12.59
Current: 9.4

6.73
12.59
PFCF 28.60
TECH's PFCF is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 28.60 )
TECH' s 10-Year PFCF Range
Min: 17.73   Max: 37.34
Current: 28.6

17.73
37.34
POCF 25.83
TECH's POCF is ranked higher than
94% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 25.83 )
TECH' s 10-Year POCF Range
Min: 15.71   Max: 31.39
Current: 25.83

15.71
31.39
EV-to-EBIT 22.09
TECH's EV-to-EBIT is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 22.09 )
TECH' s 10-Year EV-to-EBIT Range
Min: 10.4   Max: 23.5
Current: 22.09

10.4
23.5
PEG 12.48
TECH's PEG is ranked higher than
96% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 12.48 )
TECH' s 10-Year PEG Range
Min: 1.01   Max: 15.08
Current: 12.48

1.01
15.08
Shiller P/E 30.90
TECH's Shiller P/E is ranked higher than
98% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 30.90 )
TECH' s 10-Year Shiller P/E Range
Min: 20.88   Max: 52.05
Current: 30.9

20.88
52.05
Current Ratio 6.60
TECH's Current Ratio is ranked higher than
79% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. TECH: 6.60 )
TECH' s 10-Year Current Ratio Range
Min: 3.27   Max: 21.99
Current: 6.6

3.27
21.99
Quick Ratio 5.32
TECH's Quick Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.41 vs. TECH: 5.32 )
TECH' s 10-Year Quick Ratio Range
Min: 2.82   Max: 21.04
Current: 5.32

2.82
21.04
Days Inventory 130.40
TECH's Days Inventory is ranked higher than
88% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 130.40 )
TECH' s 10-Year Days Inventory Range
Min: 63.05   Max: 192.76
Current: 130.4

63.05
192.76
Days Sales Outstanding 58.38
TECH's Days Sales Outstanding is ranked higher than
85% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 114.29 vs. TECH: 58.38 )
TECH' s 10-Year Days Sales Outstanding Range
Min: 40.81   Max: 66.4
Current: 58.38

40.81
66.4

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.30
TECH's Dividend Yield is ranked higher than
58% of the 198 Companies
in the Global Biotechnology industry.

( Industry Median: 1.15 vs. TECH: 1.30 )
TECH' s 10-Year Dividend Yield Range
Min: 0.39   Max: 1.82
Current: 1.3

0.39
1.82
Dividend Payout 0.40
TECH's Dividend Payout is ranked higher than
95% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 0.40 )
TECH' s 10-Year Dividend Payout Range
Min: 0.3   Max: 0.48
Current: 0.4

0.3
0.48
Dividend growth (3y) 4.80
TECH's Dividend growth (3y) is ranked higher than
77% of the 86 Companies
in the Global Biotechnology industry.

( Industry Median: 12.10 vs. TECH: 4.80 )
TECH' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 14
Current: 4.8

0
14
Yield on cost (5-Year) 1.97
TECH's Yield on cost (5-Year) is ranked higher than
62% of the 202 Companies
in the Global Biotechnology industry.

( Industry Median: 1.39 vs. TECH: 1.97 )
TECH' s 10-Year Yield on cost (5-Year) Range
Min: 0.59   Max: 2.76
Current: 1.97

0.59
2.76
Share Buyback Rate 0.10
TECH's Share Buyback Rate is ranked higher than
95% of the 886 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. TECH: 0.10 )
TECH' s 10-Year Share Buyback Rate Range
Min: 2   Max: -2.9
Current: 0.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 19.96
TECH's Price/Tangible Book is ranked higher than
62% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 9.29 vs. TECH: 19.96 )
TECH' s 10-Year Price/Tangible Book Range
Min: 4.15   Max: 32.42
Current: 19.96

4.15
32.42
Price/DCF (Projected) 1.93
TECH's Price/DCF (Projected) is ranked higher than
97% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 1.93 )
TECH' s 10-Year Price/DCF (Projected) Range
Min: 1.27   Max: 12.77
Current: 1.93

1.27
12.77
Price/Median PS Value 1.00
TECH's Price/Median PS Value is ranked higher than
89% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 2.46 vs. TECH: 1.00 )
TECH' s 10-Year Price/Median PS Value Range
Min: 0.26   Max: 2.74
Current: 1

0.26
2.74
Price/Graham Number 5.46
TECH's Price/Graham Number is ranked higher than
91% of the 1359 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. TECH: 5.46 )
TECH' s 10-Year Price/Graham Number Range
Min: 1.96   Max: 10.66
Current: 5.46

1.96
10.66
Earnings Yield (Greenblatt) 4.50
TECH's Earnings Yield (Greenblatt) is ranked higher than
95% of the 1255 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. TECH: 4.50 )
TECH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.3   Max: 9.6
Current: 4.5

4.3
9.6
Forward Rate of Return (Yacktman) 5.46
TECH's Forward Rate of Return (Yacktman) is ranked higher than
70% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 15.72 vs. TECH: 5.46 )
TECH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 5.4   Max: 26.5
Current: 5.46

5.4
26.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:TE1.Germany,
Techne Corp is engaged in the development, manufacture and sale of biotechnology products and clinical diagnostic controls. Its business is segmented into two areas - Biotechnology and Hematology. The Biotechnology segment offers proteins, such as cytokines, and enzyme substrates and inhibitors; antibodies, including polyclonal and monoclonal antibodies; immunoassays comprising quantikine kits for the detection of human and animal proteins, and immunoassays that allow researchers to quantify a specific analyte in a biological fluids sample; clinical diagnostic immunoassay kits consisting of erythropoietin, transferrin receptor, and beta2-microglobulin immunoassays for use as in vitro diagnostic devices; flow cytometry products, such as fluorochrome labeled antibodies and kits; intracellular cell signaling products, including antibodies, phospho-specific antibodies, antibody arrays, active caspases, kinases, phosphatases, and enzyme-linked immunosorbant assays to measure the activity of apoptotic and signaling molecules; and natural and synthetic chemical compounds for use as agonists, antagonists, and inhibitors of various biological functions by investigators. The Hematology segment provides a range of hematology controls and calibrators for impedance and laser type cell counters; and hematology control products for use as proficiency testing tools by laboratory certifying authorities. The Company serves biotechnology research market and the clinical diagnostics market.
» More Articles for TECH

Headlines

Articles On GuruFocus.com
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
Discounted cash flow Jul 17 2011 
Chuck Akre MA, AMT, ESGR, ROST, TECH, KMB; Sells WRB, CRI, GLRE, RP, XOM Feb 13 2011 
Techne Corp. Reports Operating Results (10-Q) Feb 09 2011 
Techne Corp. Reports Operating Results (10-Q) Nov 09 2010 
Techne Corp. Reports Operating Results (10-K) Aug 27 2010 
Chuck Royce’s Top Predictable Companies: MEDNAX, Techne Corp., ITT Educational Services, Exactech May 17 2010 
Techne Corp. Reports Operating Results (10-Q) May 07 2010 
Comment for Buffett-Munger Screener - Good Companies at Fair or Undervalued Prices Apr 23 2010 
Techne Corp. Reports Operating Results (10-Q) Feb 08 2010 

More From Other Websites
BIO-TECHNE CORP Financials Feb 14 2015
BIO-TECHNE CORP Files SEC form 10-Q, Quarterly Report Feb 09 2015
Techne Q2 Earnings, Revenues Miss Estimates but Grow Y/Y - Analyst Blog Feb 04 2015
Q2 2015 Techne Corp Earnings Release - Before Market Open Feb 03 2015
BIO-TECHNE CORP Files SEC form 8-K, Results of Operations and Financial Condition, Other Events,... Feb 03 2015
Techne misses Street 2Q forecasts Feb 03 2015
Techne misses Street 2Q forecasts Feb 03 2015
Bio-Techne Releases Second Quarter Fiscal 2015 Results Feb 03 2015
Bio-Techne Declares Dividend Feb 03 2015
Bio-Techne Launches Simple Plex Platform Feb 02 2015
Bio-Techne To Host Conference Call On February 3, 2015 To Announce Second Quarter Financial Results Jan 27 2015
Bio-Techne Launches Simple Plex Platform Jan 22 2015
Zacks Rank #1 Additions for Monday - Tale of the Tape Jan 19 2015
Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division Nov 25 2014
BIO-TECHNE CORP Files SEC form 10-Q, Quarterly Report Nov 10 2014
Techne on an Acquisition Spree, Buys CyVek for $60M Nov 05 2014
BIO-TECHNE CORP Files SEC form 8-K, Change in Directors or Principal Officers, Amendments to... Nov 04 2014
Techne Corp. (TECH) Q1 Earnings, Revenues Miss Estimates Nov 04 2014
Bio-Techne Announces Agreement to Acquire Cyvek Nov 04 2014
Bio-Techne Announces Agreement To Acquire CyVek Nov 04 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK